UBS AM
TSHA icon

UBS AM’s Taysha Gene Therapies TSHA Stock Holding History

UBS AM’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.86M Buy
272,600
+6,805
+3% +$40.3K ﹤0.01% 2082
2026
Q1 		$1.19M Buy
265,795
+98,295
+59% +$457K ﹤0.01% 2278
2025
Q4 		$921K Buy
+167,500
New +$813K ﹤0.01% 2167
2020
Q4 		– Sell
-200,000
Closed -$4.48M – 2583
2020
Q3 		$4.48M Buy
+200,000
New +$4.7M ﹤0.01% 1197

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM's TSHA Position: Q2 2026 in Review

UBS AM increased its Taysha Gene Therapies (TSHA) stake by 2.6% in Q2 2026, buying an estimated $40.3K and bringing the position to 272,600 shares worth $1.86M. The position accounts for ﹤0.01% of the portfolio, ranked #2082.

UBS AM first reported a position in TSHA in Q3 2020 and has held it in 4 quarters since. The position peaked at $4.48M in Q3 2020. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • UBS AM held 272,600 shares of Taysha Gene Therapies worth $1.86M as of Q2 2026.
  • UBS AM bought 6,805 Taysha Gene Therapies shares in Q2 2026, an estimated $40.3K.
  • Taysha Gene Therapies made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2082 holding.
  • UBS AM first reported a position in Taysha Gene Therapies in Q3 2020 and has held it in 4 quarters since.
  • UBS AM's Taysha Gene Therapies position peaked at $4.48M in Q3 2020.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.